Volumina Medical raises USD 21 million to advance regenerative medicine

Volumina Medical, a pioneering medtech based at the Biopôle in Epalinges, has successfully secured USD 21 million in Series A funding.

Founded as a spin-off from the EPFL in 2018, Volumina Medical specializes in regenerative medicine for dermatology and plastic surgery. The company’s cutting-edge solution, Adipearl, is an innovative injectable dermal filler designed to regenerate soft tissues, addressing a critical need for millions worldwide seeking reconstruction or aesthetic enhancements post-surgery or due to disease.

The recent funding milestone will be instrumental in expanding clinical trials involving Adipearl, spearheaded by leading Key Opinion Leaders (KOLs) in Europe. These trials are crucial for accumulating extensive clinical evidence necessary to navigate Adipearl towards commercialization, promising to offer natural and lasting solutions to enhance patient health and well-being.

Reflecting on the initial patient responses to Adipearl, CEO and Co-Founder Amélie Béduer said: “I will never forget the intensity of the smiles on the face of the first patients that were treated with Adipearl. Together with this funding round, it is providing us a lot of confidence and an extremely high energy to continue to develop Volumina Medical and offer our solution to millions of patients.”

Answering a true need of patients

In the company’s press release, the enthusiasm is echoed by Silvia Scherer, Chairwoman of the board, who noted the market’s growing interest in Adipearl and its promising outcomes: “This new funding round provides a strong commitment and allows the Volumina team to continue its steady progress and answer a true need of patients.”

Volumina Medical’s journey is backed by a consortium of initial financiers including BlueOcean Ventures, ZKB, Skyviews Life Sciences, Clinique La Prairie, and various private investors. The company has also garnered support from multiple programs and institutions like Innosuisse, Venture Kick, Venturelab, and the European Institute of Innovation and Technology (EIT Health), marking its remarkable ascent in the regenerative medicine arena.